SecBot SecBot
8-K ·Filed May 13, 2026

SPRO

Spero Therapeutics, Inc.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-221567
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Q1 results are backward-looking and secondary to the June 18 FDA decision on tebipenem HBr. Monitor for any pre-PDUFA documents or commentary. Approval could trigger milestone payments and a re-rating; denial would likely require strategic alternatives given minimal revenue.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.76
T+0 close · May 13, 2026 · via day close
Latest settled
−55.43%
T+60 · $1.23
Vs SPY
−59.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $2.76entry
  2. T+1 · 6mo ago +1.09%α +2.31% · $2.79
  3. T+5 · 6mo ago −2.54%α −1.82% · $2.69
  4. T+20 · 5mo ago +3.26%α +4.12% · $2.85
  5. T+60 · 3mo ago −55.43%α −59.02% · $1.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics reported Q1 2026 results with revenue plunging 95% to $0.3M as the Phase 3 trial ended, but net loss narrowed to $7.2M from $13.9M due to lower R&D expenses. Cash position grew to $56.1M, and guidance for runway into 2028 was reaffirmed. The market remains focused on the June 18 PDUFA decision for tebipenem HBr, which will determine the company's near-term trajectory.

Key Financial Metrics

EPS
−$0.13
Revenue
$258.0K
-95.6% YoY

Key Facts

  • Q1 2026 net loss of $7.2M vs $13.9M in Q1 2025 (narrowed 48%)
  • Diluted EPS: -$0.13 vs -$0.25 year over year
  • Total revenue fell to $0.3M from $5.9M, a 95% decline
  • R&D expenses dropped to $2.9M from $13.6M as PIVOT-PO trial completed
  • Cash and cash equivalents: $56.1M at March 31, 2026, up from $40.3M at year-end
  • Cash runway guidance maintained into 2028
  • PDUFA date for tebipenem HBr NDA remains June 18, 2026
  • GSK is the licensing partner for tebipenem HBr commercialization

Financial Impact

Revenue collapsed to near zero as collaboration milestones concluded; operating loss improved by ~$7M as clinical trial costs fell. No change to cash runway guidance.

revenuenet losscash

Risk Factors

  • FDA denial or complete response letter for tebipenem HBr
  • Revenue dependence on GSK milestones; no approved products
  • Dilution risk if additional financing needed post-PDUFA decision

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-221567
Document: d147628d8k.htm0001193125-26-221567
Document: 0001193125-26-221567-index-headers.html0001193125-26-221567
Document: 0001193125-26-221567-index.html0001193125-26-221567
Document: 0001193125-26-221567.txt0001193125-26-221567
8-K Data (Synthetic)0001193125-26-221567

Track record

17 reports on SPRO

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026